Invivyd Inc. (IVVD)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability and immune response of VYD2311 on its own, an mRNA COVID-19 vaccine on its own, and VYD2311 given together with a COVID-19 vaccine in healthy adults, the New Haven, Connecticut-based company said.
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd Q1 Earnings Call Highlights
Invivyd NASDAQ: IVVD said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to its VYD2311 development efforts.
Invivyd Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 43,931 | $48,324.1 | $33,875.19 | -$14,448.91 | -29.9% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 60,400 | $78,520 | $47,148.24 | -$31,371.76 | -39.95% |
 Ashish Sharma DGS Capital Management LLC | 11,300 | $12,430 | $8,964.29 | -$3,465.71 | -27.88% |
 Li Peng China Universal Asset Management Co. Ltd. | 69,178 | $142,765.09 | $55,515.34 | -$87,249.75 | -61.11% |
| TK Taro Kuriyama Axq Capita LLP | 19,984 | $25,979 | $15,769.37 | -$10,209.63 | -39.3% |
Invivyd Inc. (IVVD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Invivyd Inc. ever had a stock split?
Invivyd Inc. Profile
| Biotechnology Industry | Healthcare Sector | William E. Duke Jr. CEO | NASDAQ (NMS) Exchange | 00534A102 CUSIP |
| US Country | 122 Employees | - Last Dividend | - Last Split | 6 Aug 2021 IPO Date |
Overview
Invivyd, Inc. is a pioneering clinical-stage biopharmaceutical enterprise focusing on the development and commercialization of innovative antibody-based solutions aimed at combating infectious diseases, primarily within the United States. Originally founded as Adagio Therapeutics, Inc., the company underwent a rebranding to Invivyd, Inc. in September 2022, signaling a refined focus and expanded aspirations in the infectious disease arena. Since its establishment in 2020, Invivyd has been at the forefront of addressing global health challenges, leveraging its collaboration with esteemed institutions like Adimab, LLC, and the Scripps Research Institute. These partnerships underline Invivyd’s commitment to harnessing cutting-edge science in the pursuit of groundbreaking treatments and preventive measures against infectious diseases, most notably against the backdrop of the coronavirus pandemic and seasonal influenza threats.
Products and Services
Invivyd, Inc.’s product pipeline is distinguished by its targeting of critical infectious diseases, with an emphasis on utilizing monoclonal antibodies for treatment and prevention. Here's a look at their key developments:
- Adintrevimab: This lead product candidate stands out as a potent neutralizing antibody undergoing Phase 3 clinical trials. It is specifically designed for the treatment and prevention of coronavirus disease, showcasing Invivyd’s active role in responding to the ongoing global health crisis triggered by the coronavirus pandemic.
- Monoclonal Antibody Candidates (VYD222 and VYD224): These candidates are in the development stage, aimed at providing broad-spectrum neutralizing protection against SARS-CoV-2. Their development is a testament to Invivyd’s expertise in engineering antibodies that offer a strong defense against the evolving strains of coronavirus.
- Seasonal Influenza Prevention Candidates: While still in the discovery stage, these candidates signal Invivyd’s foresight in addressing other pervasive infectious challenges, such as seasonal influenza. These efforts exemplify the company’s dedication to broadening its impact beyond the current pandemic, towards a future where seasonal influenza can be more effectively managed or possibly eradicated.
In addition, Invivyd’s collaborative engagements, notably with Adimab, LLC for the discovery and optimization of proprietary antibodies, and its research partnership with the Scripps Research Institute, highlight the company’s strategy of leveraging external expertise and resources to accelerate its discovery and development processes. Such collaborations aim to identify promising vaccine candidates for the prevention, diagnosis, or treatment of not only influenza but also beta coronaviruses, marking a comprehensive approach towards infectious disease management.
